课题基金 / 基金详情

Roswell Park Cancer Institute Center Support Grant

Roswell Park Cancer Institute Center Support Grant
罗斯威尔帕克癌症研究所中心支持补助金
批准号:
7933236
负责人:
DONALD L TRUMP
金额:
$130.03万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2012-09-30

项目摘要

项目成果

DONALD L TRUMP的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):罗斯威尔公园癌症研究所(RPCI)自1974年NCI指定此类中心以来一直被公认为综合癌症中心,现在要求在未来五年内继续获得联邦支持。作为一个独立的研究、教育和临床癌症护理研究所,RPCI在布法罗市中心附近占地27英亩,临床和研究空间已扩大到近160万平方英尺,比上一次审查期间增加了16%。 RPCI服务于纽约西部约150万的人群,RPCI肿瘤登记处每年记录超过3,400例新发癌症患者。RPCI与布法罗大学和Hauptman-Woodward结构生物学研究所有着密切的合作关系,但它是一个完全独立的实体,由唐纳德·特朗普博士、CCSG PI和RPCI总裁/首席执行官组成,只对RPCI董事会负责。 自上次竞争性更新以来,RPCI已显着增长,表现为:1)招聘了100多名新的临床医生和研究人员,其中43名是新的CCSG成员; 2)NCI资金总额增加了74%,同行评审资金总额增加了44%; 3)药物启动的干预性临床试验的应计费用增加73%,所有干预性试验的应计费用增加44%; 4)增加了4个新的共享资源,机构投资超过200万美元,以及(5)开放了一个新的177,000 gsf的最先进的研究大楼,该大楼容纳了计划成员实验室和共享资源。随着教师队伍的发展,还招聘了三名高级领导人。此外,还为新成立的RPCI癌症健康差异研究办公室招聘了一名主任。作为RPCI内科学发展的一部分,一个新的疾病特异性研究计划,前列腺计划,已在本次更新中增加,使RPCI共有六个科学计划,还包括癌症预防和人口科学,细胞应激和生物物理治疗,遗传学,分子靶点和实验治疗以及肿瘤免疫学和免疫治疗。 凭借强有力的领导和机构承诺,RPCI将继续专注于招募有才华的研究人员,以进一步扩大针对遗传学,研究成像和癌症健康差异领域的研究工作。
英文摘要
DESCRIPTION (provided by applicant): The Roswell Park Cancer Institute (RPCI) has been continuously recognized as a Comprehensive Cancer Center since the NCI designation of such centers in 1974 and is now requesting continued federal support for the next five years. A free-standing research, education and clinical cancer care Institute, RPCI occupies a 27 acre campus near downtown Buffalo and has expanded to nearly 1.6M gsf of clinical and research space, a 16% increase since the last review period. RPCI serves a population base of ~1.5M in Western New York where the RPCI tumor registry is recording more than 3,400 new cancer patients per year. RPCI has strong collaborations with the University of Buffalo and the Hauptman-Woodward Institute for Structural Biology, but is a fully independent entity with Dr. Donald Trump, CCSG PI and RPCI President/CEO, answering only to the RPCI Board of Directors. Since the last competitive renewal, the RPCI has grown significantly as demonstrated by: 1) the recruitment of over 100 new faculty clinicians and researchers of which 43 are new CCSG members; 2) a 74% increase in total NCI funding and a 44% increase in total peer-reviewed funding; 3) a 73% increase in accrual to investigator-initiated, interventional clinical trials and a 44% increase to accrual in all interventional trials; 4) the addition of 4 new shared resources with an institutional investment of over $2.0 M and (5) the opening of a new, 177,000 gsf, state-of-the-art research building housing Program member laboratories and Shared Resources. With the growth in faculty has also come the recruitment of three Senior Leaders. In addition, a director for the newly created RPCI Office of Cancer Health Disparities Research has also been recruited. As part of the scientific growth within RPCI, a new disease-specific Research Program, the Prostate Program, has been added in this renewal bringing RPCI to a total of six Scientific Programs that also include Cancer Prevention & Population Sciences, Cell Stress & Biophysical Therapies, Genetics, Molecular Targets & Experimental Therapeutics and Tumor Immunology & Immunotherapy. With strong leadership and institutional commitment, RPCI will continue to focus on recruiting talented investigators to further expand research efforts targeting areas in genetics, investigational imaging and cancer health disparities.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pathology
Pharmacokinetics
Small Animal BioImage
Investigational Drug
国内基金
海外基金
Park7激活Nrf2/HO-1通路抑制铁死亡,缓解ONC模型中RGCs损伤的机制研究
  • 批准号:
    JCZRQNB202600263
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
SERCA2通过PARK7-ROS抑制铁死亡减轻肾纤维化的机制研究
CircGLIS3通过调控YY1/PARK7轴抑制乳腺癌中铁死亡发生的机制研究
  • 批准号:
    2026JJ82239
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    谭小浪
  • 依托单位:
棕色脂肪外泌体miR-23a靶向调控PARK2/PGC1α轴抑制非酒精性脂肪肝病进展的机制研究
  • 批准号:
    JCZRQN202501149
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: